What do systematic reviews say?

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  RR 2.45 [1.72, 3.49]
  3 studies · 464 participants
  Moderate

Oral miltefosine (50 mg for 28 days) vs 28 days on/off placebo regimen

Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  RR 3.96 [1.49, 10.48]
  1 study · 133 participants
  Moderate

Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA) (20 mg/kg/d for 20 days) vs placebo + IVMA

• Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  High